| Umsatz in Mio. | - |
| Operatives Ergebnis (EBIT) in Mio. | - |
| Jahresüberschuss in Mio. | - |
| Umsatz je Aktie | - |
| Gewinn je Aktie | -2,83 $ |
| Gewinnrendite | - |
| Umsatzrendite | - |
| Return on Investment | - |
| Marktkapitalisierung in Mio. | 8.167 $ |
| KGV (Kurs/Gewinn) | -15,89 |
| KBV (Kurs/Buchwert) | - |
| KUV (Kurs/Umsatz) | - |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | - |
| Aktienanzahl | 180,28 Mio. |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Biotechnologie |
| Aktientyp | Stammaktie |
| +36,05% | Bain Capital Investors LLC |
| +5,92% | Perceptive Advisors LLC |
| +4,14% | venBio Select Advisor LLC |
| +3,93% | Vanguard Group Inc |
| +1,95% | BlackRock Inc |
| +1,94% | State Street Corporation |
| +1,78% | Fidelity International Ltd |
| +1,29% | Eckert Corp |
| +1,28% | NORGES BANK |
| +1,28% | Paradigm Biocapital Advisors LP |
| +1,18% | Soros Fund Management LLC |
| +1,04% | Citigroup Inc |
| +1,03% | Pentwater Capital Management LP |
| +1,03% | Geode Capital Management, LLC |
| +1,03% | Marshall Wace Asset Management Ltd |
| +0,98% | FMR Inc |
| +0,81% | Millennium Management LLC |
| +0,65% | Farallon Capital Management, L.L.C. |
| +0,64% | AllianceBernstein L.P. |
| +0,63% | Segantii Capital Management Ltd |
| +31,41% | Weitere |
| 0,00% | Streubesitz |
